Cited 0 times in Scipus Cited Count

Prognostic value of negative interim 2-[(1)(8)F]-fluoro-2-deoxy-d-glucose PET/CT in diffuse large B-cell lymphoma

Authors
Kwon, SH | Kang, DR  | Kim, J | Yoon, JK  | Lee, SJ  | Jeong, SH  | Lee, HW  | An, YS
Citation
Clinical radiology, 71(3). : 280-286, 2016
Journal Title
Clinical radiology
ISSN
0009-92601365-229X
Abstract
AIM: To assess the prognostic value of negative interim combined 2-[(18)F]-fluoro-2-deoxy-d-glucose ((18)F-FDG) positron-emission tomography/computed tomography (PET/CT) in patients with diffuse large B-cell lymphoma (DLBCL). MATERIALS AND METHODS: Ninety-two patients with histologically proven DLBCL were enrolled. All of the patients underwent (18)F-FDG PET/CT at diagnosis, and interim PET/CT after the second cycle of chemotherapy with rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisolone (R-CHOP). Negative interim PET/CT was defined as the disappearance of all abnormal (18)F-FDG uptake compared to the pretreatment PET/CT image, as determined by visual assessment. The clinical outcome of patients was estimated as progression-free survival (PFS), and the prognostic significance of clinicopathological and imaging parameters were assessed using the Cox proportional hazards model. RESULTS: Thirty-six patients (39.1%) showed lymphoma progression within a median follow-up of 30.8 months. According to univariate analysis, Ann Arbor stage, serum lactate dehydrogenase level, Eastern Cooperative Oncology Group scale, International Prognostic Index (IPI) score, and maximum standardised uptake values on initial PET/CT were significant prognostic factors for PFS (all p<0.05). Among these parameters, only the IPI score was an independent predictor for PFS (p=0.044). Survival of patients with a high IPI score (>/=3) was poorer than those with a low IPI score (0-2: p<0.001). CONCLUSION: Despite a negative interim (18)F-FDG PET/CT, approximately 39% of DLBCL patients showed progression during follow-up. Although the negative PET/CT was obtained during chemotherapy, it is important to closely follow-up patients, especially those with a high IPI score.
MeSH

DOI
10.1016/j.crad.2015.11.019
PMID
26732889
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Medical Humanities & Social Medicine
Journal Papers > School of Medicine / Graduate School of Medicine > Nuclear Medicine & Molecular Imaging
Journal Papers > School of Medicine / Graduate School of Medicine > Hematology-Oncology
Ajou Authors
강, 대용  |  안, 영실  |  윤, 준기  |  이, 수진  |  이, 현우  |  정, 성현
Files in This Item:
There are no files associated with this item.
Export

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse